Inmune Bio

Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus on the bottom line, with a Net Loss of -$1.27M vs. -$5.90M expected and EPS of -$0.05 vs. -$0.21 expected. The variance was primarily driven by a massive $4.40M R&D tax credit benefit from the Australian government, which resulted in a net R&D benefit of $0.80M for the quarter instead of a net expense. While revenue remained at $0 as expected for this clinical-stage biotech, management reported the pivotal trial for lead program CORDStrom is complete, with UK regulatory filing targeted for late Q3/early Q4 2026.